Results 51 to 60 of about 2,404 (154)

Validation of Small‐Molecule Entry Inhibitors Targeting the Respiratory Syncytial Virus

ChemMedChem, Volume 21, Issue 20, 28 October 2026.
Respiratory syncytial virus (RSV) remains a major cause of severe respiratory disease, while effective treatments for acute infection are still limited. We screened small‐molecule RSV entry inhibitors and investigated promising hits through resynthesis and antiviral testing.
Christina Karhan, Svenja M. Sake, Melanie Urbanek‐Quaing, Diletta Bergamo, Jessica Rückert, Jiabin Huang, Christina Grethe, Antonia P. Gunesch, Anne Kühnel, Birthe Reinecke, Nicole Fischer, Thomas F. Schulz, Thomas Pietschmann, Anna K. H. Hirsch   +13 more
wiley   +1 more source

Pharmacokinetics, Immunogenicity, and Safety of a Modified YTE Antibody in Healthy Adults

Clinical Pharmacology in Drug Development, Volume 15, Issue 10, October 2026.
Abstract REGN17092, a fully human immunoglobulin (Ig) G1 antibody with M252Y/S254T/T256E (YTE) modification in the Fc portion, was assessed in a first‐in‐human study (ClinicalTrials.gov, NCT05923424). REGN17092 was designed to target the severe acute respiratory coronavirus 2 (SARS‐CoV‐2) S protein.
Maria Rosario, Jan de Hoon, Flonza Isa, Kenneth Turner, Jing Li, Joel Kantrowitz, Samit Ganguly, Sasha Fraser, Zhongqing Will He, Hong Yan, Ana Gonzalez Ortiz, Lori Faria, Ingeborg Heirman, Alina Baum, Thomas D Norton, Yogesh Patel, Veronica Mas Casullo, John D Davis   +17 more
wiley   +1 more source

Cost-effectiveness of immunization strategies to protect infants against respiratory syncytial virus in the Netherlands

Human Vaccines & Immunotherapeutics
The European Medicines Agency has authorized two interventions to prevent lower respiratory tract disease due to respiratory syncytial virus (RSV-LRTD) in infants: nirsevimab, a monoclonal antibody, and bivalent stabilized prefusion F subunit maternal ...
Annefleur C. Langedijk, Floris van den Dungen, Lisette Harteveld, Jennie van den Boer, Lucy Smit, Ahuva Averin, Erin Quinn, Mark Atwood, Amy Law, Diana Mendes, Marlies van Houten   +10 more
doaj   +1 more source

Cross‐Neutralizing and Broadly Neutralizing Human Antibodies Against Nonenveloped Viruses

European Journal of Immunology, Volume 56, Issue 10, October 2026.
In this review article, Marchand et al. compare cross ‐ and broadly ‐neutralizing human antibodies against non ‐ enveloped viruses from several major families, discussing their structural characteristics, neutralization mechanisms and relevance for the development of antiviral vaccines and therapeutics.
Sarah Marchand, Samy Taouli, Dorian McIlroy   +2 more
wiley   +1 more source

First Phylodynamic Analysis of HRSV‐A and HRSV‐B in Rio de Janeiro, Brazil, Reveals Recurrent Dispersals From the Megalopolis Center to Suburban Cities

Journal of Medical Virology, Volume 98, Issue 10, October 2026.
ABSTRACT Human respiratory syncytial virus (HRSV) is the leading cause of acute lower respiratory tract infections in infants and represents a major burden to public health systems worldwide. Despite its epidemiological relevance, genomic surveillance of HRSV in Brazil remains limited.
Alessandra Pavan Lamarca, Melise Chaves Silveira, Renata Campos Azevedo, Maria Angélica Arpon Marandino Guimarães, Claudia Maria Braga de Mello, Adriana Cardoso Camargo, Leandro Magalhães de Souza, Alexandra Lehmkuhl Gerber, Ana Paula C. Guimarães, Andréa Cony Cavalcanti, Ana Tereza Ribeiro Vasconcelos   +10 more
wiley   +1 more source

Cost-Effectiveness of Nirsevimab and Clesrovimab in Preventing Respiratory Syncytial Virus Lower Respiratory Tract Disease in Infants in the United States: A Modeling Study

Infectious Diseases and Therapy
Introduction Respiratory syncytial virus (RSV) is the leading cause of infant hospitalizations in the United States, with a significant seasonal impact on healthcare resources. Long-acting monoclonal antibodies (mAbs), nirsevimab and clesrovimab, provide
Benjamin Yarnoff, Matthieu Beuvelet, Samira Soudani, Maureen P. Neary, Erin N. Hodges, Ayman Chit, Maribel Tribaldos, Veronica Gabriel, Robert Musci, Jeroen Geurtsen, Leonard R. Krilov   +10 more
doaj   +1 more source

Vaccination in pediatric transplantation—General recommendations. A position paper by the European Reference Network TransplantChild

Journal of Pediatric Gastroenterology and Nutrition, Volume 83, Issue 4, Page 624-636, October 2026.
Abstract Infectious diseases remain a leading cause of morbidity and mortality among pediatric transplant recipients, despite significant advances in transplantation management. Vaccination is the most effective strategy to prevent infections; however, its efficacy is hindered in solid organ transplant (SOT) and hematopoietic stem cell transplant (HSCT)
Valeria Casotti, Francesco Saglio, Adriana Balduzzi, Peter Barany, Vibeke Brix Christensen, Simona Buelli, Daniele Donà, Maja Klaudel‐Dreszler, Sara Mosca, Andrea Pietrobattista, Michele Pinon, Giusy Ranucci, Lars Wennberg, Lorenzo D'Antiga, ERN TransplantChild Working Group, Claudia Vittori, Manuela Tumino, B. Ruben Brandsema, Lisa Swartling, Silvia Garazzino, Carlo Pace Napoleone, Kai Lehmberg, Isabella Guzzo, Charlotte Roy, Nicola Pradegan, Silvia Simo Nebot, Maria Herthelius, Angelo Mazza, Enrico Aidala, Oleg Godik, Victoria Bordon Cueto De Braem, Marco Busutti, Emily Claire Argento, Marc Garcia Lorenzo, Timo Jahnukainen, Zoryana Ivanyuk   +35 more
wiley   +1 more source

Impact van nirsevimab op pediatrische RSV-infecties in België in 2024-2025. Een analyse van de routine sentinel-surveillancegegevens van Sciensano

We schatten dat 35 tot 45% van de ziekenhuisopnames is voorkomen door de introductie van nirsevimab. We schatten dat de introductie van nirsevimab heeft geleid tot 35-45% minder ziekenhuisopnames voor een RSV-infectie bij kinderen jonger dan 5 jaar.
T. Braeye, A. Lajot, L. Cornelissen, L. De Mot, S. Hanoteaux, Y. Dockx, B.E.L.S.A.R.I.N.E.Tresearch group, S. Denayer, Y. Lafort, I. Van Evercooren, M. Fonnesu, Y. Dupont, K. Blot, M. Vandromme, P. Mpakaniye, M.U. Paz   +15 more
core   +1 more source

Real-world effectiveness of nirsevimab against respiratory syncytial virus in pediatric practice: the Piemonitorab study

Italian Journal of Pediatrics
Background Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infections (LRTIs) in pediatric populations, resulting in a substantial burden of disease.
Elisa Funiciello, Alessia Spadavecchia, Celeste Cagnazzo, Lorenza Ferrara, Bartolomeo Griglio, Antonino Sottile, Paola Berchialla, Franca Fagioli, on behalf of the Piemonitorab Study Group   +8 more
doaj   +1 more source

Impact du nirsevimab sur les infections pédiatriques au VRS en Belgique en 2024-2025 : une analyse des données de surveillance sentinelle de routine de Sciensano

Nous estimons que 35 à 45 % des hospitalisations ont été évitées grâce à l’introduction du nirsevimab. Nous estimons que l’introduction du nirsevimab a permis de diminuer de 35 à 45 % les hospitalisations liées à une infection au VRS chez les enfants de ...
T. Braeye, A. Lajot, L. Cornelissen, L. De Mot, S. Hanoteaux, Y. Dockx, B.E.L.S.A.R.I.N.E.Tresearch group, S. Denayer, Y. Lafort, I. Van Evercooren, M. Fonnesu, Y. Dupont, K. Blot, M. Vandromme, P. Mpakaniye, M.U. Paz   +15 more
core   +1 more source